Transgene Biotek will sell one of its bio-generic products 'Erythropoietin', to Tss Export GmbH for a total consideration of $5 million (over Rs 26 crore). The management of Transgene has formalised the sale of technology of one of its bio-generic products, Erythropoietin to 'Tss Export GmbH FZE' for a total consideration of $5 million.

Erythropoietin is a hormone produced by the kidney that promotes the formation of red blood cells in the bone marrow. This sale of technology is expected to be completed during a period of approximately 5-6 months. With the market for Erythropoietin set to become very competitive, the management of Transgene has decided to monetise some of the dormant technologies through either out-licensing or strategic partnerships within and outside India. The company had earlier out-licensed two of its technologies - a recombinant Hepatitis B Vaccine to one of the largest vaccine producers in the world, and more recently Orlistat to one of the biggest Indian pharma companies with a significant presence on the global arena.

Transgene Biotek Share Price

3.75 -0.07 (-1.83%)
29-Apr-2025 10:30 View Price Chart
Peers
Company Name CMP
Apollo Hospital Ent. 7001.50
Max Healthcare Inst 1105.00
Narayana Hrudayalay 1800.15
Aster DM Healthcare 512.55
Global Health 1195.00
View more..
© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.
×
Please wait your portfolio is updating...